Business & Industry
Daiichi Sankyo Enter AI Oncology Collaboration with Tempus
Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with...
Business & Industry
FDA Seeks Input on National Priority Voucher Pilot Program
The U.S. Food and Drug Administration has initiated a new phase of stakeholder engagement for its national priority voucher pilot program, announcing a public meeting scheduled for June 12, 2026, alongside a Federal Register Notice seeking industry feedback. The...
Business & Industry
Merck Acquires Terns Pharmaceuticals in $6.7 Billion Deal
Merck, known as MSD outside the United States and Canada, confirmed it has signed a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion. The transaction, priced at $53.00 per share in cash, has...
News
What Hospitals Must Get Right When Scaling Their Provider Networks
Healthcare organizations across the country are expanding their provider networks to meet growing demand. Population growth, physician shortages in certain specialties, and the rise of large integrated health systems are pushing hospitals to recruit more clinicians and extend their...
BioPharma
Axplora $60M Investment Expands HPAPI Manufacturing Capacity
Axplora has reached a key milestone in its ongoing investment strategy, advancing a $60 million programme dedicated to strengthening HPAPI manufacturing capabilities at its Farmabios site in Gropello Cairoli. The latest development involves the construction of a new 4,500...
Business & Industry
ICON Advarra Partnership Builds Research-Ready Trial Model
ICON, a world-leading clinical research organisation, has formalised a definitive partnership agreement with Advarra to introduce a new research-ready trial model designed to reshape how clinical trials are conducted. The collaboration brings together ICON’s global clinical trial solutions with...
Business & Industry
Novartis China Investment Expands R&D and Manufacturing
Novartis is stepping up its presence in China with a fresh wave of capital deployment, underscoring the country’s growing role in global pharmaceutical strategy. The company confirmed a Novartis China investment exceeding 3.3 billion Chinese yuan (roughly $480 million),...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read